Oh! Championship Series last weekend as an off-meta deck beat out the favored Ryzeal and Maliss. Let's see who won.

Oh! TCG could be slow at times with one monster being Summoned per turn. Ultimate Offering is a Continuous Trap that allows ...

Zhen, MD, associate professor in the clinical research division of Fred Hutchinson Cancer Center, discusses the results of ... of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), this ...

Continuing our series of Arizona Diamondbacks player reviews, talented left-handed starting pitching prospect Yu-Min Lin is our last projection of the current team. The projection below is a ...

[N]on-Hispanic Black patients were statistically significantly more likely to have a more advanced disease (stage III, 29% vs 25%; stage IV, 47% vs 45%) at diagnosis compared with non-Hispanic ...

Racial disparities in cancer stage at diagnosis among older adults with gastrointestinal cancers in the southeastern United States. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal ...

Colorectal cancer can seem a lot like some common gastrointestinal (GI) disorders, including hemorrhoids, irritable bowel syndrome (IBS), an infection, or inflammatory bowel diseases (IBD), such ...

"Data presented at ASCO GI highlight botensilimab and balstilimab’s potential to redefine colorectal cancer treatment, delivering remarkable outcomes in neoadjuvant MSS CRC," said Dr. Steven O ...

Claudin 18.2, or CLDN18.2, is a top target for GI cancer drug research. This past October, Astellas Pharma’s Vyloy became the first FDA-approved CLDN18.2-targeting drug. Vyloy, a monoclonal ...